ESM-1 regulates cell growth and metastatic process through activation of NF-κB in colorectal cancer

被引:76
作者
Kang, Yun Hee [1 ]
Ji, Na Young [1 ]
Han, Seung Ro [5 ]
Lee, Chung Il [1 ]
Kim, Jae Wha [1 ]
Yeom, Young Il [1 ]
Kim, Young Ho [2 ]
Chun, Ho Kyung [2 ]
Kim, Jong Wan [3 ]
Chung, Jin Woong [4 ]
Ahn, Dong Kuk [5 ]
Lee, Hee Gu [1 ]
Song, Eun Young [1 ]
机构
[1] KRIBB, Med Genom Res Ctr, Taejon 305806, South Korea
[2] Samsung Med Ctr, Seoul, South Korea
[3] Dankook Univ, Sch Med, Dept Lab Med, Cheonan, South Korea
[4] Dong A Univ, Dept Biol Sci, Pusan, South Korea
[5] Kyungpook Natl Univ, Sch Dent, Dept Oral physiol, Taegu, South Korea
基金
新加坡国家研究基金会;
关键词
ESM-1; Colorectal cancer; Cell growth; Metastatic process; NF-kappa B activation; GLYCOGEN-SYNTHASE KINASE-3; NECROSIS-FACTOR-ALPHA; ENDOCAN EXPRESSION; TARGET GENES; MOLECULE-1; MIGRATION; SURVIVAL; IDENTIFICATION; LOCALIZATION; INHIBITOR;
D O I
10.1016/j.cellsig.2012.06.004
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
In our previous study, we reported that endothelial cell specific molecule-1 (ESM-1) was increased in tissue and serum from colorectal cancer patients and suggested that ESM-1 can be used as a potential serum marker for early detection of colorectal cancer. The aim of this study was to evaluate the role of ESM-1 as an intracellular molecule in colorectal cancer. ESM-1 expression was knocked down by small interfering RNA (siRNA) in colorectal cancer cells. Expression of ESM-1 siRNA decreased cell survival through the Akt-dependent inhibition of NF-kappa B/I kappa B pathway and an interconnected reduction in phospho-Akt, -p38. -ERK1, -RSK1, -GSK-3 alpha/beta and -HSP27, as determined by a phospho-MAPK array. ESM-1 silencing induced G(1) phase cell cycle arrest by induction of PTEN, resulting in the inhibition of cyclin D1 and inhibited cell migration and invasion of COLO205 cells. Consistently, ESM-1 overexpression in HCT-116 cells enhanced cell proliferation through the Akt-dependent activation of NF-kappa B pathway. In addition, ESM-1 interacted with NF-kappa B and activated NF-kappa B promoter. This study demonstrates that ESM-1 is involved in cell survival, cell cycle progression, migration, invasion and EMT during tumor invasion in colorectal cancer. Based on our results, ESM-1 may be a useful therapeutic target for colorectal cancer. Crown Copyright (C) 2012 Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1940 / 1949
页数:10
相关论文
共 38 条
[1]   Nuclear factor-κ-B:: The enemy within [J].
Aggarwal, BB .
CANCER CELL, 2004, 6 (03) :203-208
[2]  
BARTKOVA J, 1995, ONCOGENE, V10, P775
[3]   Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression [J].
Basseres, D. S. ;
Baldwin, A. S. .
ONCOGENE, 2006, 25 (51) :6817-6830
[4]   Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity [J].
Béchard, D ;
Gentina, T ;
Delehedde, M ;
Scherpereel, A ;
Lyon, M ;
Aumercier, M ;
Vazeux, R ;
Richet, C ;
Degand, P ;
Jude, B ;
Janin, A ;
Fernig, DG ;
Tonnel, AB ;
Lassalle, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (51) :48341-48349
[5]   Activation of AKT kinases in cancer: Implications for therapeutic targeting [J].
Bellacosa, A ;
Kumar, CC ;
Di Cristofano, A ;
Testa, JR .
ADVANCES IN CANCER RESEARCH, VOL 94, 2005, 94 :29-+
[6]  
Bubici C, 2006, HISTOL HISTOPATHOL, V21, P69, DOI 10.14670/HH-21.69
[7]   Akt2: a role in breast cancer metastasis [J].
Chau, NM ;
Ashcroft, M .
BREAST CANCER RESEARCH, 2004, 6 (01) :55-57
[8]   Eotaxin-2 and colorectal cancer: A potential target for immune therapy [J].
Cheadle, Eleanor J. ;
Riyad, Kallingal ;
Subar, Daren ;
Rothwell, Dominic G. ;
Ashton, Garry ;
Batha, Hayley ;
Sherlock, David J. ;
Hawkins, Robert E. ;
Gilham, David E. .
CLINICAL CANCER RESEARCH, 2007, 13 (19) :5719-5728
[9]   Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis [J].
Chung, JH ;
Eng, C .
CANCER RESEARCH, 2005, 65 (18) :8096-8100
[10]   A decade of tyrosine kinases: from gene discovery to therapeutics [J].
Craven, RJ ;
Lightfoot, H ;
Cance, WG .
SURGICAL ONCOLOGY-OXFORD, 2003, 12 (01) :39-50